International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7843642
Original Article
Antibiotic Susceptibility Pattern of Nitrofurantoin VS Fosfomycin in Urinary Tract Infections Caused by Escherichia Coli in a Tertiary Care Hospital, Visakhapatnam, Andhra Pradesh
 ,
 ,
 ,
 ,
Published
April 19, 2023
Abstract
Aims and Objectives: Aim of the study is to estimate prevalence of Escherichia coli among clinically suspected Urinary Tract Infection cases and comparison of antibiogram between Nitrofurantoin VS Fosfomycin as the first line agent for treatment of Urinary Tract Infection caused by Escherichia coli. Materials and Methods: The study was conducted on urine samples over a period of six months (August 2022 to January 2023) during which 3215 urine samples were taken from patients at King George Hospital, Visakhapatnam and were processed for bacterial culture and sensitivity. Out of 3215 urine samples,816 were culture positives among them, 373 were Escherichia coli isolates and these isolates were subjected to Antibiotic susceptibility by Kirby-Bauer disc diffusion Method according to the Clinical Laboratory Standard Institute Guidelines 2022 in Microbiology department, Andhra Medical College. Results: Among 816 culture positives, 373 isolates were Escherichia coli (45.71%), followed by Klebsiella sps (26.5%), others were Acinetobacter sps, Candida sps, Pseudomonas sps, Proteus sps, Enterococcus sps, Citrobacter sps and MRSA. The Antibiotic susceptibility of Escherichia coli isolates to Nitrofurantoin and Fosfomycin was 89.54% and 73.99% respectively. Conclusion: This study helps us to understand that Escherichia coli is the common Urinary pathogen causing Urinary Tract Infection. The use of Nitrofurantoin and Fosfomycin against Escherichia coli indicates that these two drugs are therapeutic alternatives for Urinary Tract Infection. Among these two drugs, Nitrofurantoin is most effective in the empirical treatment of Urinary Tract Infections.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
2042 Views
276 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved